Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 20 Key Players companies in Calcium channel blocker
by Most Patent Filings in the China in 2022

The Calcium channel blocker top 20 is Discovery PatSnap’ annual ranking of the top 20 Most Patent Filings Calcium channel blocker Key Players in the China. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2022, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
Calcium channel blockers (CCB), calcium channel antagonists or calcium antagonists are a group of medications that disrupt the movement of calcium (Ca²⁺) through calcium channels. Calcium channel blockers are used as antihypertensive drugs, i.e., as medications to decrease blood pressure in patients with hypertension. CCBs are particularly effective against large vessel stiffness, one of the common causes of elevated systolic blood pressure in elderly patients. Calcium channel blockers are also frequently used to alter heart rate (especially from atrial fibrillation), to prevent peripheral and cerebral vasospasm, and to reduce chest pain caused by angina pectoris.
#
Company Name
Region
Tech Topics
Total
1
Patent: 13
2
Gastroenterology,Health care,Medicine,
...[+2]
Patent: 10
3
Patent: 4
4
Biology,Medicine,Health care,
...[+2]
Patent: 3
5
Patent: 2
6
Patent: 2
7
Patent: 2
8
Patent: 1
9
Patent: 1
10
Patent: 1
11
Patent: 1
12
Patent: 1
13
Patent: 1
14
Patent: 1
15
Patent: 1
16
Patent: 1
17
Shanghai Innostar Biotechnology Co Ltd
Patent: 1
18
Patent: 1
19
Patent: 1
20
Patent: 1
Page generation time: Jun 29 2025